Pradžia › T ląstelių limfoma › Kalifornija
T ląstelių limfoma klinikiniai tyrimai Kalifornija
13 tyrimai dėl T ląstelių limfoma ieško dalyvių vietose Kalifornija.
Miestai Kalifornija
Oficialus tyrimo tekstas (anglų kalba)
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
- Cedars-Sinai Medical Center, Los Angeles
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-10-02 · NCT04803201Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
- City of Hope National Medical Center, Duarte
- University of California, Irvine, Irvine
- University of California San Francisco, San Francisco
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-25 · NCT06561048BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
- City of Hope National Medical Center, Duarte
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-18 · NCT04752826Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
- Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank
- City of Hope Comprehensive Cancer Center, Duarte
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
- ir dar 4
Renkami dalyviai3 fazė
Amžius nuo 18 iki 75 · Visoms lytims · Atnaujinta 2026-09-14 · NCT06724237A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL
- City of Hope Comprehensive Cancer Cente, Duarte
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-09 · NCT06854653Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
- Rady Children's Hospital, San Diego
Renkami dalyviai2 fazė
Amžius nuo 1 iki 18 · Visoms lytims · Atnaujinta 2026-08-10 · NCT06390319Duvelisib Maintenance for the Treatment of Peripheral T-Cell Lymphomas
- City of Hope Medical Center, Duarte
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-05 · NCT07293403Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma
- City of Hope Medical Center, Duarte
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-07-31 · NCT03011814Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas
- City of Hope Medical Center, Duarte
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-06-05 · NCT07278856A Registry for People With T-cell Lymphoma
- City of Hope Cancer Center (Data collection only), Duarte
- UNIVERSITY OF CALIFORNIA SAN DIEGO (Data collection only), San Diego
- University of California San Francisco (Data collection only), San Francisco
- ir dar 1
Renkami dalyviaiStebimasis tyrimas
Visi amžiai · Visoms lytims · Atnaujinta 2026-05-20 · NCT05978141MB-105 in Patients With CD5 Positive T-cell Lymphoma
- University of San Diego (UCSD)-Moores Cancer Center, San Diego
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2025-10-03 · NCT06534060Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
- City of Hope Medical Foundation, Duarte
- University of Southern California, Los Angeles
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2025-09-22 · NCT04234048Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- Children's Hospital Los Angeles, Los Angeles
- Children's Hospital Orange County, Orange
- UCSF School of Medicine, San Francisco
Renkami dalyviai1 fazė
Amžius nuo 1 iki 21 · Visoms lytims · Atnaujinta 2024-12-06 · NCT05476770Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.